Press release
GLP-1 Agonists Redefining Diabetes and Obesity Treatment: New Approvals, Expanding Indications, and Next-Gen Pipelines | DelveInsight
According to DelveInsight's latest report, "Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape & Market Forecast", (https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr) the Glucagon-like Peptide-1 (GLP-1) agonists market is projected to expand at a significant CAGR through 2034. The GLP-1 therapeutics market is primarily driven by the rising global diabetes epidemic, with approximately 537 million adults living with diabetes as of 2021. Type 2 diabetes mellitus accounts for over 85% of all diabetes cases, with about 1.4 million new cases diagnosed in the United States alone each year. The condition disproportionately affects older adults, with prevalence exceeding 25% among those over 65 years of age.
The GLP-1 epidemiology landscape continues to evolve as researchers gain deeper insights into the prevalence and distribution of type 2 diabetes and obesity across different demographic groups. DelveInsight's analysis indicates a substantial eligible patient population for GLP-1 therapy, with both diabetes and obesity rates projected to increase throughout the forecast period, further driving demand for effective therapeutic interventions.
Learn more about GLP-1 agonists patient trends by leveraging DelveInsight's expert analysis on GLP-1 epidemiological data @ https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
The report also discusses the Glucagon-like Peptide-1 agonists treatment landscape which encompasses various administration options, including injectable and oral formulations, providing patients and healthcare providers with flexible therapeutic approaches.
The current GLP-1 drug market is dominated by several key players and their approved medications. Regulatory bodies have approved multiple GLP-1 receptor agonists, including TRULICITY (Eli Lilly), BYETTA/BYDUREON (AstraZeneca), VICTOZA (Novo Nordisk), OZEMPIC/WEGOVY (Novo Nordisk), and MOUNJARO/ZEPBOUND (Eli Lilly and Company), among others. These medications have demonstrated efficacy in glycemic control and, in some cases, significant weight management benefits, further solidifying their position in the treatment paradigm for metabolic disorders.
The GLP-1 pipeline shows promising results, with several innovative candidates advancing through clinical development. Some of the therapies include orforglipron (Eli Lilly and Company), survodutide (Boehringer Ingelheim), danuglipron (Pfizer), and retatrutide (Eli Lilly and Company), among others. These emerging therapies aim to address current treatment gaps, improve efficacy profiles, and reduce side effects, potentially reshaping the competitive landscape in the coming years.
To uncover key insights into the rapidly growing GLP-1 agonists competitive dynamics and emerging innovations, visit https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Recent developments highlight the expanding applications of GLP-1 agonists beyond traditional diabetes management. In July 2024, a significant milestone was reached when the MHRA approved semaglutide to reduce the risk of serious heart problems in obese or overweight adults, making it the first weight-loss drug approved in the UK as a preventative treatment for cardiovascular disease. Additionally, Roche announced promising early weight loss results from Phase I trials of its oral GLP-1 receptor agonist in July 2024.
Further, in November 2024, the FDA approved a generic version of BYETTA (AstraZeneca) by Amneal Pharmaceuticals. This was followed by the approval of a generic version of another GLP-1 receptor agonist, VICTOZA (Novo Nordisk), in December 2024, manufactured by Hikma Pharmaceuticals, suggesting a growing demand in the GLP-1 agonists landscape.
In conclusion, the Glucagon-like Peptide-1 agonists market is poised for significant growth through 2034, driven by the increasing prevalence of type 2 diabetes and obesity worldwide. With a robust pipeline of innovative therapies from leading pharmaceutical companies, the market is expected to witness transformative changes in treatment paradigms.
As new formulations and delivery methods emerge, patient outcomes are likely to improve, potentially expanding the applications of GLP-1 agonists beyond diabetes management. However, challenges such as pricing, reimbursement, and market access will continue to shape the competitive landscape. Stakeholders in the healthcare industry should closely monitor these developments to capitalize on the expanding opportunities in the GLP-1 therapeutics market.
Access DelveInsight's detailed analysis to understand how advancements in drug delivery systems and expanding indications are revolutionizing diabetes and obesity management @ https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of GLP-1 Agonists
4. Key Events
5. GLP-1 Agonists Market Overview At A Glance
6. Background And Overview
7. GLP-1 Agonists Target Population
8. GLP-1 Agonists Marketed Drugs
9. GLP-1 Agonists Emerging Drugs
10. GLP-1 Agonists: The 7MM Analysis
11. GLP-1 Agonists Unmet Needs
12. SWOT Analysis
13. KOL Views
14. GLP-1 Agonists Market Access and Reimbursement
15. Appendix
16. Delveinsight Capabilities
17. Disclaimer
18. About DelveInsight
Related Reports
Diabetes Pipeline Insight
https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Diabetes Pipeline Insight provides comprehensive insights about the Diabetes pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Diabetes companies, including vTv Therapeutics (VTVT), Tonghua Dongbao Pharmaceutical, Eli Lilly and Company (LLY), Celon Pharma (CLN), Sciwind Biosciences, AstraZeneca (AZN), Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, and Chong Kun Dang Pharmaceutical among others.
Contact Us
Arpit Anand
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GLP-1 Agonists Redefining Diabetes and Obesity Treatment: New Approvals, Expanding Indications, and Next-Gen Pipelines | DelveInsight here
News-ID: 4136844 • Views: …
More Releases from DelveInsight Business Research LLP
West Nile Encephalitis Treatment Market Size Report 2032: Major Companies, Emerg …
DelveInsight's "West Nile Encephalitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the West Nile Encephalitis, historical and forecasted epidemiology as well as the West Nile Encephalitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the West Nile Encephalitis Market Share @ West Nile Encephalitis Market Outlook- https://www.delveinsight.com/sample-request/west-nile-encephalitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the…
FAP Inhibitor Market Poised for Transformational Growth by 2040 Led by Emerging …
Key Takeaways
• As per DelveInsight's analysis, the total market size of FAP inhibitors in the 7MM is expected to surge significantly by 2040, driven by anticipated launches of several emerging FAP inhibitor therapies targeting a range of cancer indications.
• The report provides the total potential number of patients across multiple cancer indications, with the US accounting for approximately 205,000 incident NSCLC cases, 236,500 incident prostate cancer cases, 152,800 metastatic colorectal…
X Linked Hypophosphatemia Treatment Market Size Report 2032: Major Companies, Em …
DelveInsight's "X Linked Hypophosphatemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X Linked Hypophosphatemia, historical and forecasted epidemiology as well as the X Linked Hypophosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the X Linked Hypophosphatemia Market Share @ X Linked Hypophosphatemia Market Outlook- https://www.delveinsight.com/sample-request/x-linked-hypophosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
X-Linked Hypophosphatemia (XLH) is a…
Ehlers-Danlos Syndrome Treatment Market Size Report 2032: Major Companies, Emerg …
DelveInsight's "Ehlers-Danlos Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Ehlers-Danlos Syndrome, historical and forecasted epidemiology as well as the Ehlers-Danlos Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Ehlers-Danlos Syndrome Market Share @ Ehlers-Danlos Syndrome Market Outlook- https://www.delveinsight.com/sample-request/ehlers-danlos-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Ehlers-Danlos Syndrome (EDS) refers to a group of hereditary connective…
More Releases for Agonists
GLP-1 Agonists Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Agonists Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Injection), By Molecule (Dulaglutide, Liraglutide, Semaglutide, Lixisenatide, Exenatide, Tirzepatide), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, Market Outlook And Industry Analysis 2031"
The global GLP-1 agonists market is estimated to reach over USD 10.32 billion by 2031, exhibiting a CAGR of…
Muscarinic Agonists Market Size [2023-2031] - Alcon Inc., Paladin Labs Inc.
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Muscarinic Agonists Market.
The Muscarinic Agonists Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy. The Muscarinic Agonists…
Selective Agonists Market 2022 Size & Industry Forecast by 2027
This latest report provides an in-depth analysis of the Global Selective Agonists Market size, share, recent developments, and trends. According to the report, the industry is expected to develop at a substantial rate between 2022 and 2027. The study compiles data from industry experts and numerous prominent players in the market to give a concise summary and in-depth analysis of the market. Aside from that, the research includes a complete…
Glucagon Like Peptide-1 (GLP-1) Agonists Market - key players covered:GSK, Sanof …
Los Angeles, United State, –The report titled Global Glucagon Like Peptide-1 (GLP-1) Agonists Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer…
Global Adrenergic Agonists Industry Market Analysis & Forecast 2018-2023
Global Adrenergic Agonists Market 2018 Insights, Forecast To 2023. Global Adrenergic Agonists Market report exhibits the far-reaching Global Adrenergic Agonists Industry estimation (esteem, request, supply, creation likewise utilization), parts the data further by producers, districts, types, and applications from 2018 to 2023. This report has set up the market situation in an organized way, accentuating the modern advancement, unmistakable players connected with from the present Global Adrenergic Agonists Market ,…
Research focused on the Global Sigma Receptor Agonists Market
MarketResearchReports.Biz is providing you Retail Market Research report of "Sigma Receptor Agonists-Pipeline Insights, 2017".
Latest Report, Sigma Receptor Agonists-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Sigma Receptor Agonists. The Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other…
